Figures & data
Table 1. Physical characteristics of ChiNPs with different pharmaceutical groups.
Figure 3. SiRNA loading capacity of ChiNP (140 kDa) with various IGF-1 R siRNA concentrations. Naked siRNA as control (CTRL), lane 1: 25 nM, lane 2: 50 nM and lane 3:100 nM.
![Figure 3. SiRNA loading capacity of ChiNP (140 kDa) with various IGF-1 R siRNA concentrations. Naked siRNA as control (CTRL), lane 1: 25 nM, lane 2: 50 nM and lane 3:100 nM.](/cms/asset/bb3fa071-5ff0-42ce-9dd9-de155bc5c2de/ianb_a_1307212_f0003_b.jpg)
Figure 4. The stability analysis of siRNA-loaded ChiNPs in serum and heparin challenges. (A) The stability of siRNA-loaded ChiNP/CMD against FBS after 72 h incubation. Naked siRNA was considered as control (CTRL). (B) The stability of siRNA-loaded ChiNP/CMD against different volumes of heparin (2 μg/mL) after 1 h incubation. Naked siRNA was considered as positive control (CTRL).
![Figure 4. The stability analysis of siRNA-loaded ChiNPs in serum and heparin challenges. (A) The stability of siRNA-loaded ChiNP/CMD against FBS after 72 h incubation. Naked siRNA was considered as control (CTRL). (B) The stability of siRNA-loaded ChiNP/CMD against different volumes of heparin (2 μg/mL) after 1 h incubation. Naked siRNA was considered as positive control (CTRL).](/cms/asset/8d1b65c5-e838-41e1-b0a2-a162bd63d102/ianb_a_1307212_f0004_b.jpg)
Figure 5. IGF-1R siRNA and DOX releasing assay at different time and pH conditions. (A) IGF-1R siRNA release curve of ChiNP/siRNA/CMD in PBS with pH 5.5 and 7.4. (B) DOX release curve of ChiNP/DOX/CMD in PBS with pH 5.5 and 7.4.
![Figure 5. IGF-1R siRNA and DOX releasing assay at different time and pH conditions. (A) IGF-1R siRNA release curve of ChiNP/siRNA/CMD in PBS with pH 5.5 and 7.4. (B) DOX release curve of ChiNP/DOX/CMD in PBS with pH 5.5 and 7.4.](/cms/asset/2185448c-4102-4220-bc6e-240585d6beab/ianb_a_1307212_f0005_b.jpg)
Figure 6. Combination of IGF-1R siRNA and DOX synergistically improved cytotoxicity in A549 human lung cancer cell line in a dose and time-dependent manner at 24 h (A) and 48 h (B). CTRL represents no treated cell control. Data shown as means ± SD of three independent experiments.
![Figure 6. Combination of IGF-1R siRNA and DOX synergistically improved cytotoxicity in A549 human lung cancer cell line in a dose and time-dependent manner at 24 h (A) and 48 h (B). CTRL represents no treated cell control. Data shown as means ± SD of three independent experiments.](/cms/asset/f28e682e-1a74-4f59-8aa7-0eb4761a2d63/ianb_a_1307212_f0006_b.jpg)
Figure 7. Flow cytometry of A549 cells using Annexin V–FITC, (A) no treatment, (B) treatment with Chi/CMD, (C) free DOX, (D) Chi/siRNA/CMD, (E) Chi/DOX/CMD and (F) Chi/siRNA/DOX/CMD.
![Figure 7. Flow cytometry of A549 cells using Annexin V–FITC, (A) no treatment, (B) treatment with Chi/CMD, (C) free DOX, (D) Chi/siRNA/CMD, (E) Chi/DOX/CMD and (F) Chi/siRNA/DOX/CMD.](/cms/asset/1b15244d-3c25-478a-a0dd-585badeb2d27/ianb_a_1307212_f0007_c.jpg)
Figure 8. The effects of nanoparticles delivery of IGF-1R siRNA and DOX on apoptosis of A549 human non-small cell lung cancer cell. CTRL represents no treated cell control. Data shown as means ± SD of three independent experiments.
![Figure 8. The effects of nanoparticles delivery of IGF-1R siRNA and DOX on apoptosis of A549 human non-small cell lung cancer cell. CTRL represents no treated cell control. Data shown as means ± SD of three independent experiments.](/cms/asset/61c273b2-4af1-406f-8ec2-a63c24d667a3/ianb_a_1307212_f0008_b.jpg)